Blar i SIHF Open Archive på forfatter "Lundin, Knut Erik Aslaksen"

Viser treff 1-3 av 3

    • Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials 

      Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Peer reviewed; Journal article, 2020)
      Background: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn's disease ...

    • Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 

      Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)
      BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not ...

    • A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease 

      Schuppan, Detlef; Maki, Markku; Lundin, Knut Erik Aslaksen; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari; Langhorst, Jost; Hovde, Øistein; Lähdeaho, Marja-Leena; Fucso, Stefano; Schumann, Michael; Török, Helga-Paula; Kupcinskas, Jouzas; Zopf, Yurdagul; Lohse, Ansgar W.; Scheinin, Mika; Kull, Karin; Biedermann, Luc; Byrnes, Valerie; Stellmach, Andreas; Jahnsen, Jørgen; Zeitz, Jonas; Mohrbacher, Ralf; Greinwald, Roland (Peer reviewed; Journal article, 2021)
      Background: In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase ...